REFERENCES
2. Page DB, Yuan J, Redmond D, Wen YH, Durack JC, et al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res 2016;4:835-44.
3. Looney TJ, Duose DY, Lowman G, Linch E, Hajjar J, et al. Haplotype analysis of the T-cell receptor beta (TCRB) locus by long-amplicon TCRB repertoire sequencing. JIPO 2019;2:137-143.
4. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, et al. TCR convergence in individuals treated with immune checkpoint inhibition for cancer. Front Immunol 2020;10:2985.
5. Mellert H, Foreman T, Jackson L, Maar D, Thurston S, et al. Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma. J Mol Diagn 2017;19:404-16.
6. ThermoFisher Scientific. Oncomine TCR Beta Assay: User Guide. Revision A.0 Pleasanton, CA: Author; 2018.
7. Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, et al. Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One 2016;11:e0166354.
8. Pestano G, Jensen-Long L. Developing liquid biopsy diagnostic testing for cancer immunotherapy selection in NSCLC patients. MLO. Mar 22nd, 2018. Available from https://www.mlo-online.com/molecular/dna-rna/article/13009462/developing-liquid-biopsy-diagnostic-testing-for-cancer-immunotherapy-selection-in-nsclc-patients [Last accessed on 9 Jun 2020].
